ClinicalTrials.gov Identifier | Setting | Location | Masking | Estimated enrollment | Primary endpoint | Arm |
---|---|---|---|---|---|---|
NCT00824785 | 1st line | UK | Open-label | 730 | OS | EOX, EOX + panitumumab |
NCT01248403 | 2nd line | Germany | Double blind | 500 | OS | Paclitaxel, Paclitaxel + everolimus |
NCT01170663 | 2nd line | Global | Double blinded | 633 | OS | Placebo + paclitaxel, Ramucirumab + paclitaxel |
NCT00450203 | 1st line | UK | Open Label | 1100 | OS | ECX, ECX + Bevacizumab |
NCT00917384 | 2nd line | Global | Double blinded | 315 | OS | Placebo + BSC, Ramucirumab + BSC |
NCT01512745 | 3rd line | China | Double blinded | 500 | PFS | Placebo, Apatinib |